-
EP3848035
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3848035
| EP3848035 - 1,4-DISUBSTITUTED PYRIDAZINE COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE [Right-click to bookmark this link] | Status | Grant of patent is intended Status updated on 18.09.2024 Database last updated on 18.11.2024 | |
| Former | Examination is in progress Status updated on 29.04.2022 | ||
| Former | Request for examination was made Status updated on 21.01.2022 | ||
| Former | The application has been published Status updated on 11.06.2021 | Most recent event Tooltip | 18.09.2024 | New entry: Communication of intention to grant a patent | Applicant(s) | For all designated states PTC Therapeutics, Inc. 100 Corporate Court South Plainfield, NJ 07080 / US | [2021/28] | Inventor(s) | 01 /
Babu, Suresh 225 Concord Place Pennington, NJ 08534 / US | 02 /
Bhattacharyya, Anuradha 115 Inverness Drive Edison, NJ 08820 / US | 03 /
Hwang, Seongwoo 227 Suttons Lane Edison, NJ 08817 / US | 04 /
Jani, Minakshi 29 Kiva Street Iselin, NJ 08830 / US | 05 /
Moon, Young-choon 11 Edgewood Drive Belle Mead, NJ 08502 / US | 06 /
Sydorenko, Nadiya 37 Sycamore Place Princento, NJ 08540 / US | [2021/28] | Representative(s) | Kolster Oy Ab Salmisaarenaukio 1 P.O. Box 204 00181 Helsinki / FI | [2021/28] | Application number, filing date | 21158464.4 | 11.12.2016 | [2021/28] | Priority number, date | US201562265652P | 10.12.2015 Original published format: US 201562265652 P | [2021/28] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3848035 | Date: | 14.07.2021 | Language: | EN | [2021/28] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 21.05.2021 | Classification | IPC: | A61K31/506, C07D405/12, A61P25/00, C07D201/00, A61K31/00, A61K33/00, C07D401/14, C07D413/14, C07D237/20, C07D417/04, C07D417/14, C07D471/10, C07D487/10, C07D403/12 | [2021/28] | CPC: |
A61K31/506 (EP,IL,KR,US);
A61K31/501 (EP,IL,KR,US);
C07D401/12 (EP,CN,IL,US);
A61K31/415 (EP,IL,US);
A61K31/433 (EP,IL,KR,US);
A61K31/438 (IL,KR);
A61K31/4439 (EP,IL,KR,US);
A61K31/454 (IL,KR);
A61K31/4545 (IL,KR);
A61K31/4709 (EP,IL,KR,US);
A61K31/496 (IL,KR);
A61K31/50 (EP,IL,US);
A61K31/517 (EP,IL,US);
A61K31/5377 (EP,IL,KR,US);
A61K31/55 (IL,KR);
A61K31/5513 (EP,IL,US);
A61P25/14 (IL,KR);
A61P25/28 (EP,IL,KR,US);
C07D237/20 (EP,IL,US);
C07D401/04 (EP,IL,US);
C07D401/06 (CN,IL);
C07D401/14 (EP,CN,IL,US);
C07D403/10 (EP,CN,IL,US);
C07D403/12 (EP,CN,IL,US);
C07D403/14 (EP,CN,IL,US);
C07D405/12 (EP,IL,US);
C07D405/14 (EP,CN,IL,US);
C07D409/14 (EP,CN,IL,US);
C07D413/14 (EP,CN,IL,US);
C07D417/04 (EP,IL,US);
C07D417/10 (EP,IL,US);
C07D417/12 (EP,IL,US);
C07D417/14 (EP,CN,IL,US);
C07D471/04 (CN,IL);
C07D471/08 (EP,IL,US);
C07D471/10 (EP,IL,US);
C07D487/04 (EP,CN,IL,US);
C07D487/08 (EP,CN,IL,US);
C07D487/10 (EP,CN,IL,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/08] |
| Former [2021/28] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | 1,4-DISUBSTITUIERTE PYRIDAZINVERBINDUNGEN ZUR BEHANDLUNG DER HUNTINGTON'S KRANKHEIT | [2024/40] | English: | 1,4-DISUBSTITUTED PYRIDAZINE COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | [2021/28] | French: | COMPOSÉS PYRIDAZINE 1,4-DISUBSTITUÉS POUR LE TRAITEMENT DE LA MALADIE DE HUNTINGTON | [2021/28] |
| Former [2021/28] | 1,4-DISUBSTITUIERTE PYRIDAZINVERBINDUNGEN ZUR BEHANDLUNG DER HUNTINGTON KRANKHEIT | Examination procedure | 14.01.2022 | Amendment by applicant (claims and/or description) | 14.01.2022 | Examination requested [2022/08] | 14.01.2022 | Date on which the examining division has become responsible | 02.05.2022 | Despatch of a communication from the examining division (Time limit: M04) | 07.09.2022 | Reply to a communication from the examining division | 13.09.2022 | Despatch of a communication from the examining division (Time limit: M04) | 20.01.2023 | Reply to a communication from the examining division | 19.09.2024 | Communication of intention to grant the patent | Parent application(s) Tooltip | EP16874024.9 / EP3386511 | Fees paid | Renewal fee | 22.02.2021 | Renewal fee patent year 03 | 22.02.2021 | Renewal fee patent year 04 | 22.02.2021 | Renewal fee patent year 05 | 16.12.2021 | Renewal fee patent year 06 | 20.12.2022 | Renewal fee patent year 07 | 19.12.2023 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2007003604 (NOVO NORDISK AS [DK], et al); | [Y]WO2007130383 (NEUROMEDIX INC [CA], et al); | [Y]WO2007133561 (NEUROGEN CORP [US], et al); | [Y]US2010267721 (HOHLWEG ROLF [DK], et al); | [Y]US2014051672 (CHEUNG ATWOOD KIM [US], et al); | [Y]WO2015017589 (NOVARTIS AG [CH], et al) | by applicant | WO2014028459 | WO2014116845 | WO2015017589 |